On June 24, Novartis rose 3.01% in regular trading, trading at $153.44/share, with turnover of $197 million.

On the news front, Novartis announced that its antibody-conjugated oligonucleotide drug del-brax achieved the primary endpoint and key secondary endpoints in a Phase 1/2 study, demonstrating robust target engagement and reduced muscle damage in patients with facioscapulohumeral muscular dystrophy. Del-brax is one of three potential first-in-class therapies Novartis acquired, with the other two targeting myotonic dystrophy type 1 and Duchenne muscular dystrophy respectively. The positive readout reinforces Novartis's strategic expansion into rare neuromuscular diseases through its acquisition pipeline.

Within the Pharmacy sector where Novartis belongs, the broader sector showed strength. Among individual stocks, Johnson & Johnson up 3.44%, Merck up 3.55%, Novo-Nordisk up 3.33%, Eli Lilly up 0.65%, Pfizer down 1.44%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)